Bayhill could earn more than $350M in Genentech collaboration - Silicon Valley / San Jose Business Journal:

iqukikofor.wordpress.com
San Mateo-based Bayhill's BHT-3021 is a DNA-based antigenn specific immunotherapy currently in clinical trials for patients with type 1 Under the terms of the SouthSan Francisco-based Genentech will make an upfront payment of $25 million in cash and with additional development, regulatory and sales milestone payments potentially exceedinvg $325 million. Bayhill will also receive competitives escalating royalties on annual net Bayhill will be responsible for completingthe trial, while Genentech will be responsiblwe for all future research, development, manufacturintg and commercialization efforts.
Genentech will reimburse Bayhill the remaining costss of the trial and will fund all future Under the terms of the Bayhill retains rightsto opt-in on futurre development as well as an option to co-promot e in North America. Bayhill Therapeuticsz is a clinical-stage biopharmaceutical company focused onautoimmunew diseases. Genentech is a wholly-owned memberd of the Roche Group.